These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 25480886

  • 1. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice.
    Manders SH, Kievit W, Adang E, Jansen TJ, Stolk JN, Visser H, Schilder AM, Vonkeman HE, van de Laar MA, van Riel PL.
    Ann Rheum Dis; 2015 Mar; 74(3):e24. PubMed ID: 25480886
    [No Abstract] [Full Text] [Related]

  • 2. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [Abstract] [Full Text] [Related]

  • 3. The issue of bioavailability of oral low dose methotrexate: should we choose only 10 mg of MTX a week in conjunction with anti-TNF therapy?
    Zeidler H.
    Ann Rheum Dis; 2014 Aug; 73(8):e50. PubMed ID: 24764450
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD.
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab for rheumatoid arthritis?
    Ebell M, Kripke C.
    Am Fam Physician; 2006 Feb 01; 73(3):435-6. PubMed ID: 16479667
    [No Abstract] [Full Text] [Related]

  • 6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 01; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 7. Rheumatoid arthritis.
    Burchini G, Orsi C.
    N Engl J Med; 2004 Sep 23; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
    Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.
    Ann Rheum Dis; 2009 Dec 23; 68(12):1856-62. PubMed ID: 19126559
    [Abstract] [Full Text] [Related]

  • 9. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 23; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 23; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, Burkly LC.
    Clin Ther; 2013 Aug 23; 35(8):1137-49. PubMed ID: 23928094
    [Abstract] [Full Text] [Related]

  • 15. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM.
    Ann Rheum Dis; 2005 Apr 15; 64(4):537-43. PubMed ID: 15769913
    [Abstract] [Full Text] [Related]

  • 17. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study.
    Jamnitski A, Levels JH, van den Oever IA, Nurmohamed MT.
    J Rheumatol; 2013 Jun 15; 40(6):825-30. PubMed ID: 23637327
    [Abstract] [Full Text] [Related]

  • 18. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V.
    J Rheumatol; 2006 Feb 15; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract] [Full Text] [Related]

  • 19. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK, Petersson IF, Geborek P.
    Scand J Rheumatol; 2012 Feb 15; 41(1):1-9. PubMed ID: 22118371
    [Abstract] [Full Text] [Related]

  • 20. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
    Ornetti P, Solau E, Gaudin P, Sibilia J, Berthelot JM, Puechal X, Tavernier C, Maillefert JF, Club Rhumatismes et Inflammation from the French Society of Rheumatology.
    Ann Rheum Dis; 2005 Sep 15; 64(9):1379-80. PubMed ID: 16100349
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.